“Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors (Q3099129): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: beneficiary (P889): (Q3118623)) |
(Changed an Item) |
||
| Property / beneficiary | |||
| Property / beneficiary: Q3118623 / rank | |||
Normal rank | |||
Revision as of 13:31, 6 October 2021
Project Q3099129 in Romania
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | “Natural Killer” Cell Oncoimunotherapy carrying antigen hysteric receptors |
Project Q3099129 in Romania |
Statements
7,171,850.97 Romanian Leu
0 references
1,434,370.1940000001 Euro
0.2 Euro
13 September 2021
0 references
8,493,897.32 Romanian Leu
0 references
1,698,779.4640000002 Euro
0.2 Euro
13 September 2021
0 references
84.44 percent
0 references
1 September 2016
0 references
30 November 2020
0 references
SPITALUL CLINIC JUDETEAN DE URGENTA " PIUS BRINZEU " TIMISOARA
0 references
Obiectivul principal al acestei propuneri de proiect este de a urma o abordare unica si de a dezvolta noi CARs care sunt potrivite în mod special pentru terapiile pe baza de celule NK, care reprezinta terapia personalizata anti-tumorala de ultimă ora. Ne asteptam ca acest proiect sa produca cereri de brevet internationale, care se vor traduce in cele din urma in comercializarea acestei tehnologii in Romania si in strainatate. Cunostintele obtinute in urma cercetarilor fundamentale in acest domeniu vor servi ulterior la stabilirea procedurile de lucru, reproductibile care vor ghida productia la nivel de GMP de celule pentru uz clinic pentru studii clinice suplimentare. In plus, ne propunem crearea primei banci de celule umane CAR-NKS, care poate fi dezvoltata si utilizata pentru studii clinice, in sprijinul medicinii personalizate in Romania. (Romanian)
0 references
The main objective of this project proposal is to follow a unique approach and develop new CARs that are especially suitable for NK cell therapies, which represent the latest personalised anti-tumor therapy. We expect this project to produce international patent applications, which will ultimately translate into the commercialisation of this technology in Romania and abroad. The knowledge obtained from fundamental researches in this field will then serve to establish reproducible working procedures that will guide the production of GMP cells for clinical use for further clinical trials. In addition, we aim to create the first CAR-NKS human cell bank, which can be developed and used for clinical trials, in support of personalised medicine in Romania. (English)
16 September 2021
0 references
Municipiul Timişoara, Romania
0 references
Identifiers
103662
0 references